Current breast cancer treatment has shifted to using natural ingredients such as C. zedoaria high potential and low side effects. Previous studies show that C. zedoaria active compounds used as anti-proliferative, increasing apoptosis, and anti-metastasis. However, information about the mechanism of the active compound to inhibition of CXCR4 in the carcinogenesis process unknown. CXCR4 is a specific receptor for CXCL12 and known to play an essential role in prognosis and drug target of breast cancer. This research aimed to analyze the effect of C. zedoaria active compounds as breast cancer chemotherapeutic agents through CXCR4 inhibition. Binding affinity value shows that 11 compounds from C. zedoaria have the potential to inhibit CXCR4 with the smallest binding affinity and the same binding site with Chalcone and Epirubicin. However, Stigmasterol, Campesterol, and β-sitosterol have the lowest binding affinity than the other active compound. Analysis of protein interaction shows that CXCR4 interacts with CXCL12, STAT3, and JAK2. Its protein used as a poor prognosis factor for cancer. These results indicate that C. zedoaria are active compounds and are highly potential as anti-breast cancer. Further research is needed to validate the above data.
Skip Nav Destination
Article navigation
21 April 2020
INTERNATIONAL CONFERENCE ON LIFE SCIENCES AND TECHNOLOGY (ICoLiST)
12–13 September 2019
Malang, Indonesia
Research Article|
April 21 2020
Curcuma zedoaria: Potential effect as breast cancer chemotherapeutic agents through CXCR4 inhibition
Nur Fitriana;
Nur Fitriana
c)
Biology Department, Mathematics and Natural Science Faculty, University of Brawijaya
, Indonesia
Search for other works by this author on:
Muhaimin Rifa’i;
Muhaimin Rifa’i
b)
Biology Department, Mathematics and Natural Science Faculty, University of Brawijaya
, Indonesia
Search for other works by this author on:
Widodo
Widodo
a)
Biology Department, Mathematics and Natural Science Faculty, University of Brawijaya
, Indonesia
a)Corresponding author: [email protected]
Search for other works by this author on:
AIP Conf. Proc. 2231, 040028 (2020)
Citation
Nur Fitriana, Muhaimin Rifa’i, Widodo; Curcuma zedoaria: Potential effect as breast cancer chemotherapeutic agents through CXCR4 inhibition. AIP Conf. Proc. 21 April 2020; 2231 (1): 040028. https://doi.org/10.1063/5.0002629
Download citation file:
Citing articles via
Inkjet- and flextrail-printing of silicon polymer-based inks for local passivating contacts
Zohreh Kiaee, Andreas Lösel, et al.
Design of a 100 MW solar power plant on wetland in Bangladesh
Apu Kowsar, Sumon Chandra Debnath, et al.
Effect of coupling agent type on the self-cleaning and anti-reflective behaviour of advance nanocoating for PV panels application
Taha Tareq Mohammed, Hadia Kadhim Judran, et al.
Related Content
A molecular screening of HER2 inhibitors from Curcuma zedoaria
AIP Conference Proceedings (August 2022)
In silico study of Actinium-225 (225AC) labelled pentixafor targeting CXCR4 and genetic dependency for breast cancer therapy
AIP Conf. Proc. (February 2024)
Anti-cancer potential of white turmeric extract (Curcuma zedoaria) in MCF-7 and HEPG-2 cancer cells
AIP Conf. Proc. (January 2024)
Combining CXCR4-targeted and nontargeted nanoparticles for effective unassisted in vitro magnetic hyperthermia
Biointerphases (February 2018)
Progress of JAK/STAT 3 and its inhibitors in the treatment of cancer
AIP Conf. Proc. (February 2020)